Exploring Demo Mode — data is read-onlySign Up Free
Back to protocol

Systematic Review: Screening

Identification

54 included / 1 excluded

Screening

43 included / 1 excluded

Eligibility

33 included / 0 excluded

Included

22 included / 0 excluded

Efficacy and Safety of RSVPreF Vaccine in Older Adults: Phase 3 RENOIR Trial Results

Walsh EE, Perez Marc G, Zareba AM, et al.New England Journal of Medicine (2023)

IncludedIncluded

Real-World Effectiveness of RSV Vaccination Among Medicare Beneficiaries, 2023-2024

Surie D, Bonnell L, Adams K, et al.MMWR Morbidity and Mortality Weekly Report (2024)

IncludedIncluded

ACIP Recommendations for RSV Vaccination in Adults Aged 60 Years and Older

Melgar M, Britton A, Roper LE, et al.CDC Advisory Committee on Immunization Practices (2024)

EligibilityIncluded

Burden of RSV-Associated Hospitalizations Among US Adults, 2019-2023

Havers FP, Whitaker M, Melgar M, et al.Clinical Infectious Diseases (2024)

ScreeningExcluded

Reason: Epidemiology only — no vaccine effectiveness data

Study team discussion: Data source selection and feasibility notes

Study teamInternal (2025)

IdentificationExcluded

Reason: Internal notes — not primary literature

Want to make screening decisions?

Sign up for free to unlock all features.

Sign Up Free
VaxEvidence | Real-World Evidence Platform for Vaccine Research